Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 1,696

The DOI matches its Crossref record; 292 of the 292 references it cites were found in a registry or an index.

Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology

Benson, Al B., Venook, Alan P., Al-Hawary, Mahmoud M., Arain, Mustafa A., Chen, Yi-Jen, Ciombor, Kristen K., Cohen, Stacey, Cooper, Harry S., Deming, Dustin, Farkas, Linda, Garrido-Laguna, Ignacio, Grem, Jean L., Gunn, Andrew, Hecht, J. Randolph, Hoffe, Sarah, Hubbard, Joleen, Hunt, Steven, Johung, Kimberly L., Kirilcuk, Natalie, Krishnamurthi, Smitha, Messersmith, Wells A., Meyerhardt, Jeffrey, Miller, Eric D., Mulcahy, Mary F., Nurkin, Steven, Overman, Michael J., Parikh, Aparna, Patel, Hitendra, Pedersen, Katrina, Saltz, Leonard, Schneider, Charles, Shibata, David, Skibber, John M., Sofocleous, Constantinos T., Stoffel, Elena M., Stotsky-Himelfarb, Eden, Willett, Christopher G., Gregory, Kristina M., Gurski, Lisa A. · 2021 · Journal of the National Comprehensive Cancer Network

Abstract

This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Colon Cancer focuses on systemic therapy options for the treatment of metastatic colorectal cancer (mCRC), because important updates have recently been made to this section. These updates include recommendations for first-line use of checkpoint inhibitors for mCRC, that is deficient mismatch repair/microsatellite instability-high, recommendations related to the use of biosimilars, and expanded recommendations for biomarker testing. The systemic therapy recommendations now include targeted therapy options for patients with mCRC that is HER2-amplified, or BRAF V600E mutation–positive. Treatment and management of nonmetastatic or resectable/ablatable metastatic disease are discussed in the complete version of the NCCN Guidelines for Colon Cancer available at NCCN.org. Additional topics covered in the complete version include risk assessment, staging, pathology, posttreatment surveillance, and survivorship.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.6004/jnccn.2021.0012

Cites

292 of 292 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 374

  1. 2020, Drug Administration Package Insert STIVARGA regorafenib tablets for oral use Accessed November Available at https www accessdata fda gov drugsatfda docs label lbl pdf, Food, 17
  2. Yoo, 2006, Liver resection for metastatic colorectal cancer in the age of neoadjuvant chemotherapy and bevacizumab, Clin Colorectal Cancer, 6, 202, 10.3816/CCC.2006.n.036 · doi:10.3816/ccc.2006.n.036
  3. LONSURF, 2019, Drug Administration Package Insert trifluridine tipiracil tablets for oral use Accessed November Available at https www accessdata fda gov drugsatfda docs label lbl pdf, Food, 17
  4. Panitumumab, 2017, Administration Package Insert Vectibix Accessed November Available at https www accessdata fda gov drugsatfda docs label lbl pdf, Food Drug, 17, 207
  5. Resch, 2011, Infusion reactions to the chimeric EGFR inhibitor cetuximab--change to the fully human anti-EGFR monoclonal antibody panitumumab is safe, Ann Oncol, 22, 486, 10.1093/annonc/mdq744 · doi:10.1093/annonc/mdq744
  6. Wang, 2010, KRAS mutation testing in human cancers: the pathologist’s role in the era of personalized medicine, Adv Anat Pathol, 17, 23, 10.1097/PAP.0b013e3181c6962f · DOI
  7. Guo, 2016, XELOX vs. FOLFOX in metastatic colorectal cancer: An updated meta-analysis, Cancer Invest, 34, 94, 10.3109/07357907.2015.1104689 · DOI
  8. Deenen, 2016, Upfront genotyping of DPYD*2A to individualize fluoropyrimidine therapy: a safety and cost analysis, J Clin Oncol, 34, 227, 10.1200/JCO.2015.63.1325 · DOI · Paper page
  9. Seymour, 2012, Conceptual approaches to metastatic disease, Ann Oncol, 23, x77, 10.1093/annonc/mds361 · doi:10.1093/annonc/mds361
  10. Buchler, 2014, Bevacizumab with 5-fluorouracil, leucovorin, and oxaliplatin versus bevacizumab with capecitabine and oxaliplatin for metastatic colorectal carcinoma: results of a large registry-based cohort analysis, BMC Cancer, 14, 323, 10.1186/1471-2407-14-323 · doi:10.1186/1471-2407-14-323
  11. Seymour, 2007, Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial, Lancet, 370, 143, 10.1016/S0140-6736(07)61087-3 · DOI · Paper page
  12. 2019, Drug Administration Package Insert ZIRABEVTM bevacizumab bvzr injection for intravenous use Accessed November Available at https www accessdata fda gov drugsatfda docs label lbl pdf, Food, 17, 000
  13. Nordlinger, 2013, Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial, Lancet Oncol, 14, 1208, 10.1016/S1470-2045(13)70447-9 · DOI · Paper page
  14. Hurwitz, 2004, Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer, N Engl J Med, 350, 2335, 10.1056/NEJMoa032691 · DOI · Paper page
  15. Dai, 2013, Safety of bevacizumab in treating metastatic colorectal cancer: a systematic review and meta-analysis of all randomized clinical trials, Clin Drug Investig, 33, 779, 10.1007/s40261-013-0125-6 · DOI
  16. Fong, 1997, Liver resection for colorectal metastases, J Clin Oncol, 15, 938, 10.1200/JCO.1997.15.3.938 · DOI · Paper page
  17. Foster, 1984, Treatment of metastatic disease of the liver: a skeptic’s view, Semin Liver Dis, 4, 170, 10.1055/s-2008-1040656 · doi:10.1055/s-2008-1040656
  18. Chibaudel, 2009, Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study, J Clin Oncol, 27, 5727, 10.1200/JCO.2009.23.4344 · DOI · Paper page
  19. Kurniali, 2010, Role of calcium/ magnesium infusion in oxaliplatin-based chemotherapy for colorectal cancer patients, Oncology (Williston Park), 24, 289
  20. Hochster, 2007, Use of calcium and magnesium salts to reduce oxaliplatin-related neurotoxicity, J Clin Oncol, 25, 4028, 10.1200/JCO.2007.13.5251 · doi:10.1200/jco.2007.13.5251
  21. Schmoll, 2017, “CHARTA”: FOLFOX/bevacizumab vs FOLFOXIRI/bevacizumab in advanced colorectal cancer—Final results, prognostic and potentially predictive factors from the randomized Phase II trial of the AIO, J Clin Oncol, 35, 3533, 10.1200/JCO.2017.35.15_suppl.3533 · doi:10.1200/jco.2017.35.15_suppl.3533
  22. Muratore, 2007, Asymptomatic colorectal cancer with un-resectable liver metastases: immediate colorectal resection or up-front systemic chemotherapy?, Ann Surg Oncol, 14, 766, 10.1245/s10434-006-9146-1 · DOI · Paper page
  23. OPDIVO, 2020, Drug Administration Package Insert nivolumab injection for intravenous use Accessed November Available at https www accessdata fda gov drugsatfda docs label lbl pdf, Food, 17, 071
  24. Hoff, 2004, Phase II study of capecitabine in patients with fluorouracil-resistant metastatic colorectal carcinoma, J Clin Oncol, 22, 2078, 10.1200/JCO.2004.05.072 · doi:10.1200/jco.2004.05.072
  25. Berlin, 2020, Efficacy and safety of larotrectinib in patients with TRK fusion gastrointestinal cancer, J Clin Oncol, 38, 824, 10.1200/JCO.2020.38.4_suppl.824 · doi:10.1200/jco.2020.38.4_suppl.824
  26. OPDIVO, 2020, Drug Administration Package Insert nivolumab injection for intravenous use Accessed November Available at https www accessdata fda gov drugsatfda docs label lbl pdf, Food, 17, 071
  27. Van Cutsem, 2004, Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials, Br J Cancer, 90, 1190, 10.1038/sj.bjc.6601676 · DOI · Paper page
  28. Knijn, 2011, The effect of prophylactic calcium and magnesium infusions on the incidence of neurotoxicity and clinical outcome of oxaliplatin-based systemic treatment in advanced colorectal cancer patients, Eur J Cancer, 47, 369, 10.1016/j.ejca.2010.10.006 · doi:10.1016/j.ejca.2010.10.006
  29. 2020, Drug Administration Package Insert KEYTRUDA pembrolizumab injection for intravenous use Accessed November Available at https www accessdata fda gov drugsatfda docs label lbl pdf, Food, 17, 088
  30. Miles, 2011, Reply to P. Potemski, J Clin Oncol, 29, e386, 10.1200/JCO.2010.34.1479 · doi:10.1200/jco.2010.34.1479
  31. Besora, 2018, Rechallenge with oxaliplatin and peripheral neuropathy in colorectal cancer patients, J Cancer Res Clin Oncol, 144, 1793, 10.1007/s00432-018-2691-8 · doi:10.1007/s00432-018-2691-8
  32. Allegra, 2011, Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08, J Clin Oncol, 29, 11, 10.1200/JCO.2010.30.0855 · DOI · Paper page
  33. Graham, 2018, A within-trial cost-effectiveness analysis of panitumumab compared with bevacizumab in the first-line treatment of patients with wild-type RAS metastatic colorectal cancer in the US, J Med Econ, 21, 1075, 10.1080/13696998.2018.1510409 · DOI
  34. Le, 2020, Phase II open-label study of pembrolizumab in treatment-refractory, microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: KEYNOTE-164, J Clin Oncol, 38, 11, 10.1200/JCO.19.02107 · DOI · Paper page
  35. Cassidy, 2008, Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer, J Clin Oncol, 26, 2006, 10.1200/JCO.2007.14.9898 · DOI · Paper page
  36. Tsai, 2007, Clinicopathological features and prognosis in resectable synchronous and metachronous colorectal liver metastasis, Ann Surg Oncol, 14, 786, 10.1245/s10434-006-9215-5 · doi:10.1245/s10434-006-9215-5
  37. Zimmer, 2016, Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy, Eur J Cancer, 60, 210, 10.1016/j.ejca.2016.02.024 · DOI · Paper page
  38. Sorich, 2015, Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials, Ann Oncol, 26, 13, 10.1093/annonc/mdu378 · DOI · Paper page
  39. CYRAMZA, 2020, Drug Administration Package Insert ramucirumab injection for intravenous use Accessed November Available at https www accessdata fda gov drugsatfda docs label lbl pdf, Food, 17, 037
  40. Resch, 2011, Infusion reactions to the chimeric EGFR inhibitor cetuximab--change to the fully human anti-EGFR monoclonal antibody panitumumab is safe, Ann Oncol, 22, 486, 10.1093/annonc/mdq744 · doi:10.1093/annonc/mdq744
  41. Van Cutsem, 2011, Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status, J Clin Oncol, 29, 2011, 10.1200/JCO.2010.33.5091 · DOI · Paper page
  42. Kopetz, 2020, Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG S1406) [abstract]., J Clin Oncol, 35, JCO2001994
  43. 2019, Drug Administration Package Insert TRAZIMERATM trastuzumab qyyp for injection for intravenous use Accessed November Available at https www accessdata fda gov drugsatfda docs label lbl pdf, Food, 17, 000
  44. Kurniali, 2010, Role of calcium/ magnesium infusion in oxaliplatin-based chemotherapy for colorectal cancer patients, Oncology (Williston Park), 24, 289
  45. Lee, 2007, Pulmonary resection for metastases from colorectal cancer: prognostic factors and survival, Int J Colorectal Dis, 22, 699, 10.1007/s00384-006-0218-2 · DOI
  46. Maughan, 2011, Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial, Lancet, 377, 2103, 10.1016/S0140-6736(11)60613-2 · DOI · Paper page
  47. Loprinzi, 2014, Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB/Alliance), J Clin Oncol, 32, 997, 10.1200/JCO.2013.52.0536 · doi:10.1200/jco.2013.52.0536
  48. Novmeber, 2019, Drug Administration Package Insert KANJINTI trastuzumab anns for injection for intravenous use Accessed Available at https www accessdata fda gov drugsatfda docs label lbl pdf, Food, 17, 1
  49. Koopman, 2009, Deficient mismatch repair system in patients with sporadic advanced colorectal cancer, Br J Cancer, 100, 266, 10.1038/sj.bjc.6604867 · DOI · Paper page
  50. Miles, 2011, Disease course patterns after discontinuation of bevacizumab: pooled analysis of randomized phase III trials, J Clin Oncol, 29, 83, 10.1200/JCO.2010.30.2794 · DOI · Paper page
  51. Innocenti, 2014, Dose-finding and pharmacokinetic study to optimize the dosing of irinotecan according to the UGT1A1 genotype of patients with cancer, J Clin Oncol, 32, 2328, 10.1200/JCO.2014.55.2307 · DOI
  52. Novmeber, 2019, Drug Administration Package Insert KANJINTI trastuzumab anns for injection for intravenous use Accessed Available at https www accessdata fda gov drugsatfda docs label lbl pdf, Food, 17, 1
  53. Berry, 2015, Continuous versus intermittent chemotherapy strategies in metastatic colorectal cancer: a systematic review and meta-analysis, Ann Oncol, 26, 477, 10.1093/annonc/mdu272 · DOI
  54. Kidwell, 2012, Long-term neurotoxicity effects of oxaliplatin added to fluorouracil and leucovorin as adjuvant therapy for colon cancer: results from National Surgical Adjuvant Breast and Bowel Project trials C-07 and LTS-01, Cancer, 118, 5614, 10.1002/cncr.27593 · DOI
  55. Saltz, 2004, Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor, J Clin Oncol, 22, 1201, 10.1200/JCO.2004.10.182 · DOI · Paper page
  56. Lenz, 2019, Nivolumab (NIVO) + low-dose ipilimumab (IPI) as first-line (1L) therapy in microsatellite instability-high/DNA mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): clinical update, J Clin Oncol, 37, 3521, 10.1200/JCO.2019.37.15_suppl.3521 · DOI
  57. Gupta, 2020, Pertuzumab plus trastuzumab (P+T) in patients (Pts) with colorectal cancer (CRC) with ERBB2 amplification or overexpression: Results from the TAPUR Study [abstract], J Clin Oncol, 38, 132, 10.1200/JCO.2020.38.4_suppl.132 · DOI · Paper page
  58. 2019, Drug Administration Package Insert ONTRUZANT trastuzumab dttb for injection for intravenous use Accessed November Available at https www accessdata fda gov drugsatfda docs label lbl pdf, Food, 17, 000
  59. Gamelin, 2008, Oxaliplatin-related neurotoxicity: interest of calcium-magnesium infusion and no impact on its efficacy, J Clin Oncol, 26, 1188, 10.1200/JCO.2007.15.3767 · doi:10.1200/jco.2007.15.3767
  60. Erbitux, 2020, Drug Administration Package Insert cetuximab injection for intravenous use Accessed November Available at https www accessdata fda gov drugsatfda docs label lbl pdf, Food, 17, 275
  61. Costa, 2017, REOX: evaluation of the efficacy of retreatment with an oxaliplatin-containing regimen in metastatic colorectal cancer: a retrospective single-center study, Clin Colorectal Cancer, 16, 316, 10.1016/j.clcc.2017.03.002 · DOI
  62. 2019, Drug Administration Package Insert ZIRABEVTM bevacizumab bvzr injection for intravenous use Accessed November Available at https www accessdata fda gov drugsatfda docs label lbl pdf, Food, 17, 000
  63. Zhang, 2012, Capecitabine plus oxaliplatin compared with 5-fluorouracil plus oxaliplatin in metastatic colorectal cancer: meta-analysis of randomized controlled trials, Oncol Lett, 3, 831
  64. Nishino, 2016, Anti-PD-1 inhibitor-related pneumonitis in non-small cell lung cancer, Cancer Immunol Res, 4, 289, 10.1158/2326-6066.CIR-15-0267 · DOI
  65. Goldstein, 2015, Considering efficacy and cost, where does ramucirumab fit in the management of metastatic colorectal cancer?, Oncologist, 20, 981, 10.1634/theoncologist.2015-0028 · DOI
  66. Di Nicolantonio, 2008, Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer, J Clin Oncol, 26, 5705, 10.1200/JCO.2008.18.0786 · DOI · Paper page
  67. Miles, 2011, Reply to P. Potemski, J Clin Oncol, 29, e386, 10.1200/JCO.2010.34.1479 · doi:10.1200/jco.2010.34.1479
  68. Tsai, 2007, Clinicopathological features and prognosis in resectable synchronous and metachronous colorectal liver metastasis, Ann Surg Oncol, 14, 786, 10.1245/s10434-006-9215-5 · doi:10.1245/s10434-006-9215-5
  69. 2019, Drug Administration Package Insert HERZUMA trastuzumab pkrb for injection for intravenous use Accessed November Available at https www accessdata fda gov drugsatfda docs label lbl pdf, Food, 17, 001
  70. Deenen, 2016, Reply to T. Magnes et al, J Clin Oncol, 34, 2434, 10.1200/JCO.2016.67.4374 · doi:10.1200/jco.2016.67.4374
  71. Hurwitz, 2005, Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer, J Clin Oncol, 23, 3502, 10.1200/JCO.2005.10.017 · DOI · Paper page
  72. Hurwitz, 2013, Efficacy and safety of bevacizumab in metastatic colorectal cancer: pooled analysis from seven randomized controlled trials, Oncologist, 18, 1004, 10.1634/theoncologist.2013-0107 · DOI · Paper page
  73. Yoo, 2006, Liver resection for metastatic colorectal cancer in the age of neoadjuvant chemotherapy and bevacizumab, Clin Colorectal Cancer, 6, 202, 10.3816/CCC.2006.n.036 · doi:10.3816/ccc.2006.n.036
  74. 2019, Drug Administration Package Insert TRAZIMERATM trastuzumab qyyp for injection for intravenous use Accessed November Available at https www accessdata fda gov drugsatfda docs label lbl pdf, Food, 17, 000
  75. Iwamoto, 2015, FOLFIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer after first-line bevacizumab plus oxaliplatin-based therapy: the randomized phase III EAGLE study, Ann Oncol, 26, 1427, 10.1093/annonc/mdv197 · DOI
  76. Cassidy, 2004, XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer, J Clin Oncol, 22, 2084, 10.1200/JCO.2004.11.069 · DOI · Paper page
  77. Petrelli, 2013, The predictive role of skin rash with cetuximab and panitumumab in colorectal cancer patients: a systematic review and meta-analysis of published trials, Target Oncol, 8, 173, 10.1007/s11523-013-0257-x · DOI
  78. Bailey, 2014, Increasing disparities in the age-related incidences of colon and rectal cancers in the United States, 1975-2010, JAMA Surg, 32, 1
  79. 2019, Drug Administration Package Insert MVASI bevacizumab awwb injection for intravenous use Accessed November Available at https www accessdata fda gov drugsatfda docs label lbl pdf, Food, 17
  80. Meulendijks, 2015, Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data, Lancet Oncol, 16, 1639, 10.1016/S1470-2045(15)00286-7 · DOI · Paper page
  81. Tabernero, 2014, Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial, Eur J Cancer, 50, 320, 10.1016/j.ejca.2013.09.013 · DOI · Paper page
  82. Moretto, 2016, Location of primary tumor and benefit from anti-epidermal growth factor receptor monoclonal antibodies in patients with RAS and BRAF wild-type metastatic colorectal cancer, Oncologist, 21, 988, 10.1634/theoncologist.2016-0084 · DOI
  83. Bennouna, 2013, Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial, Lancet Oncol, 14, 29, 10.1016/S1470-2045(12)70477-1 · DOI · Paper page
  84. André, 2020, Pembrolizumab in microsatellite-instability-high advanced colorectal cancer, N Engl J Med, 383, 2207, 10.1056/NEJMoa2017699 · DOI · Paper page
  85. Adenis, 2016, Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use program, BMC Cancer, 16, 412, 10.1186/s12885-016-2440-9 · DOI
  86. Hayashi, 2010, Clinicopathological analysis of recurrence patterns and prognostic factors for survival after hepatectomy for colorectal liver metastasis, BMC Surg, 10, 27, 10.1186/1471-2482-10-27 · DOI
  87. Valtorta, 2015, Assessment of a HER2 scoring system for colorectal cancer: results from a validation study, Mod Pathol, 28, 1481, 10.1038/modpathol.2015.98 · DOI · Paper page
  88. Stangl, 1994, Factors influencing the natural history of colorectal liver metastases, Lancet, 343, 1405, 10.1016/S0140-6736(94)92529-1 · DOI · Paper page
  89. Topalian, 2012, Safety, activity, and immune correlates of anti-PD-1 antibody in cancer, N Engl J Med, 366, 2443, 10.1056/NEJMoa1200690 · DOI · Paper page
  90. Peeters, 2013, Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab, J Clin Oncol, 31, 759, 10.1200/JCO.2012.45.1492 · DOI · Paper page
  91. Kubicka, 2013, Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings, Ann Oncol, 24, 2342, 10.1093/annonc/mdt231 · DOI · Paper page
  92. Erbitux, 2020, Drug Administration Package Insert cetuximab injection for intravenous use Accessed November Available at https www accessdata fda gov drugsatfda docs label lbl pdf, Food, 17, 275
  93. 2019, Drug Administration Package Insert ROZLYTREK entrectinib capsules for oral use Accessed November Available at https www accessdata fda gov drugsatfda docs label lbl pdf, Food, 17, 000
  94. Cao, 2009, A meta-analysis of randomized controlled trials comparing chemotherapy plus bevacizumab with chemotherapy alone in metastatic colorectal cancer, Int J Colorectal Dis, 24, 677, 10.1007/s00384-009-0655-9 · DOI
  95. Schmoll, 2006, Update on capecitabine in colorectal cancer, Oncologist, 11, 1003, 10.1634/theoncologist.11-9-1003 · DOI
  96. 2020, Drug Administration Package Insert ELOXATIN oxaliplatin injection for intravenous use Accessed November Available at https www accessdata fda gov drugsatfda docs label lbl pdf, Food, 17, 021759
  97. Haller, 2008, Potential regional differences for the tolerability profiles of fluoropyrimidines, J Clin Oncol, 26, 2118, 10.1200/JCO.2007.15.2090 · DOI · Paper page
  98. Ducreux, 2011, Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer, Int J Cancer, 128, 682, 10.1002/ijc.25369 · DOI · Paper page
  99. Venderbosch, 2014, Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies, Clin Cancer Res, 20, 5322, 10.1158/1078-0432.CCR-14-0332 · DOI · Paper page
  100. Deenen, 2016, Reply to T. Magnes et al, J Clin Oncol, 34, 2434, 10.1200/JCO.2016.67.4374 · doi:10.1200/jco.2016.67.4374
  101. Berlin, 2020, Efficacy and safety of larotrectinib in patients with TRK fusion gastrointestinal cancer, J Clin Oncol, 38, 824, 10.1200/JCO.2020.38.4_suppl.824 · doi:10.1200/jco.2020.38.4_suppl.824
  102. 2018, Drug Administration Package Insert VITRAKVI larotrectinib capsules for oral use Accessed November Available at https www accessdata fda gov drugsatfda docs label lbl pdf, Food, 17, 000
  103. Hurwitz, 2014, Safety and effectiveness of bevacizumab treatment for metastatic colorectal cancer: final results from the Avastin(®) Registry - Investigation of Effectiveness and Safety (ARIES) observational cohort study, Clin Oncol (R Coll Radiol), 26, 323, 10.1016/j.clon.2014.03.001 · DOI
  104. Fourrier-Réglat, 2014, Survival outcomes of bevacizumab in first-line metastatic colorectal cancer in a real-life setting: results of the ETNA cohort, Target Oncol, 9, 311, 10.1007/s11523-013-0296-3 · DOI
  105. Lee, 2007, Pulmonary resection for metastases from colorectal cancer: prognostic factors and survival, Int J Colorectal Dis, 22, 699, 10.1007/s00384-006-0218-2 · DOI
  106. Marabelle, 2020, Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study, Lancet Oncol, 21, 1353, 10.1016/S1470-2045(20)30445-9 · DOI · Paper page
  107. Kim, 2016, A phase 3 trial evaluating panitumumab plus best supportive care vs best supportive care in chemorefractory wild-type KRAS or RAS metastatic colorectal cancer, Br J Cancer, 115, 1206, 10.1038/bjc.2016.309 · DOI
  108. Henricks, 2019, A cost analysis of upfront DPYD genotype-guided dose individualisation in fluoropyrimidine-based anticancer therapy, Eur J Cancer, 107, 60, 10.1016/j.ejca.2018.11.010 · DOI
  109. Reddy, 2008, Addition of bevacizumab to irinotecan- and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases, J Am Coll Surg, 206, 96, 10.1016/j.jamcollsurg.2007.06.290 · DOI · Paper page
  110. Clancy, 2013, BRAF mutation is associated with distinct clinicopathological characteristics in colorectal cancer: a systematic review and meta-analysis, Colorectal Dis, 15, e711, 10.1111/codi.12427 · DOI
  111. Kabbinavar, 2005, Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer, J Clin Oncol, 23, 3706, 10.1200/JCO.2005.00.232 · DOI · Paper page
  112. CYRAMZA, 2020, Drug Administration Package Insert ramucirumab injection for intravenous use Accessed November Available at https www accessdata fda gov drugsatfda docs label lbl pdf, Food, 17, 037
  113. Yalcin, 2013, Bevacizumab + capecitabine as maintenance therapy after initial bevacizumab + XELOX treatment in previously untreated patients with metastatic colorectal cancer: phase III ‘Stop and Go’ study results--a Turkish Oncology Group Trial, Oncology, 85, 328, 10.1159/000355914 · DOI
  114. Petrelli, 2012, Risk of venous and arterial thromboembolic events associated with anti-EGFR agents: a meta-analysis of randomized clinical trials, Ann Oncol, 23, 1672, 10.1093/annonc/mdr592 · DOI
  115. Peeters, 2010, Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer, J Clin Oncol, 28, 4706, 10.1200/JCO.2009.27.6055 · DOI · Paper page
  116. Snoeren, 2017, Randomized phase III study to assess efficacy and safety of adjuvant CAPOX with or without bevacizumab in patients after resection of colorectal liver metastases: HEPATICA study, Neoplasia, 19, 93, 10.1016/j.neo.2016.08.010 · DOI
  117. Kopetz, 2019, Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer, N Engl J Med, 381, 1632, 10.1056/NEJMoa1908075 · DOI · Paper page
  118. Seymour, 2012, Conceptual approaches to metastatic disease, Ann Oncol, 23, x77, 10.1093/annonc/mds361 · doi:10.1093/annonc/mds361
  119. Venook, 2017, Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial, JAMA, 317, 2392, 10.1001/jama.2017.7105 · DOI · Paper page
  120. Van Cutsem, 2019, Binimetinib, encorafenib, and cetuximab triplet therapy for patients with BRAF V600E-mutant metastatic colorectal cancer: safety lead-in results from the phase III BEACON colorectal cancer study, J Clin Oncol, 37, 1460, 10.1200/JCO.18.02459 · DOI · Paper page
  121. Grothey, 2014, Bevacizumab exposure beyond first disease progression in patients with metastatic colorectal cancer: analyses of the ARIES observational cohort study, Pharmacoepidemiol Drug Saf, 23, 726, 10.1002/pds.3633 · DOI
  122. AVASTIN, 2020, Administration Package Insert bevacizumab injection for intravenous use Accessed November Available at https www accessdata fda gov drugsatfda docs label lbl pdf, Food Drug, 17, 336
  123. de Gramont, 2012, Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial, Lancet Oncol, 13, 1225, 10.1016/S1470-2045(12)70509-0 · DOI · Paper page
  124. Pawlik, 2005, Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases, Ann Surg, 241, 715, 10.1097/01.sla.0000160703.75808.7d · DOI · Paper page
  125. Loupakis, 2010, Magnitude of benefit of the addition of bevacizumab to first-line chemotherapy for metastatic colorectal cancer: meta-analysis of randomized clinical trials, J Exp Clin Cancer Res, 29, 58, 10.1186/1756-9966-29-58 · DOI
  126. De Roock, 2008, KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab, Ann Oncol, 19, 508, 10.1093/annonc/mdm496 · DOI · Paper page
  127. 2020, Drug Administration Package Insert STIVARGA regorafenib tablets for oral use Accessed November Available at https www accessdata fda gov drugsatfda docs label lbl pdf, Food, 17
  128. Wan, 2004, Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF, Cell, 116, 855, 10.1016/S0092-8674(04)00215-6 · DOI · Paper page
  129. Cunningham, 1998, Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer, Lancet, 352, 1413, 10.1016/S0140-6736(98)02309-5 · DOI · Paper page
  130. Siena, 2020, A phase II, multicenter, open-label study of trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): DESTINY-CRC01 [abstract], J Clin Oncol, 38, 4000, 10.1200/JCO.2020.38.15_suppl.4000 · DOI · Paper page
  131. O’Neil, 2015, Trying to understand differing results of FIRE-3 and 80405: does the first treatment matter more than others?, J Clin Oncol, 33, 3686, 10.1200/JCO.2015.62.8495 · DOI
  132. Liu, 2015, Retreatment with anti-EGFR based therapies in metastatic colorectal cancer: impact of intervening time interval and prior anti-EGFR response, BMC Cancer, 15, 713, 10.1186/s12885-015-1701-3 · DOI
  133. Cassidy, 2011, XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results, Br J Cancer, 105, 58, 10.1038/bjc.2011.201 · DOI · Paper page
  134. Petrelli, 2013, FOLFIRI-bevacizumab as first-line chemotherapy in 3500 patients with advanced colorectal cancer: a pooled analysis of 29 published trials, Clin Colorectal Cancer, 12, 145, 10.1016/j.clcc.2013.04.006 · DOI
  135. Cocco, 2019, Colorectal carcinomas containing hypermethylated MLH1 promoter and wild-type BRAF/KRAS are enriched for targetable kinase fusions, Cancer Res, 79, 1047, 10.1158/0008-5472.CAN-18-3126 · DOI · Paper page
  136. Cremolini, 2015, FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study, Lancet Oncol, 16, 1306, 10.1016/S1470-2045(15)00122-9 · DOI · Paper page
  137. Van Cutsem, 2009, Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer, N Engl J Med, 360, 1408, 10.1056/NEJMoa0805019 · DOI · Paper page
  138. Sartore-Bianchi, 2016, Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial, Lancet Oncol, 17, 738, 10.1016/S1470-2045(16)00150-9 · DOI · Paper page
  139. Rowland, 2016, Meta-analysis comparing the efficacy of anti-EGFR monoclonal antibody therapy between KRAS G13D and other KRAS mutant metastatic colorectal cancer tumours, Eur J Cancer, 55, 122, 10.1016/j.ejca.2015.11.025 · DOI
  140. Mattison, 2002, Implications of dihydropyrimidine dehydrogenase on 5-fluorouracil pharmacogenetics and pharmacogenomics, Pharmacogenomics, 3, 485, 10.1517/14622416.3.4.485 · DOI
  141. Botrel, 2016, Efficacy and safety of bevacizumab plus chemotherapy compared to chemotherapy alone in previously untreated advanced or metastatic colorectal cancer: a systematic review and meta-analysis, BMC Cancer, 16, 677, 10.1186/s12885-016-2734-y · DOI
  142. Kajitani, 2017, Anti-epidermal growth factor receptor antibody readministration in chemorefractory metastatic colorectal cancer, Anticancer Res, 37, 6459
  143. Giantonio, 2007, Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200, J Clin Oncol, 25, 1539, 10.1200/JCO.2006.09.6305 · DOI · Paper page
  144. Belum, 2013, Risk of hand-foot skin reaction with the novel multikinase inhibitor regorafenib: a meta-analysis, Invest New Drugs, 31, 1078, 10.1007/s10637-013-9977-0 · DOI
  145. 2020, Drug Administration Package Insert KEYTRUDA pembrolizumab injection for intravenous use Accessed November Available at https www accessdata fda gov drugsatfda docs label lbl pdf, Food, 17, 088
  146. Liu, 2014, Association of UGT1A1*28 polymorphisms with irinotecan-induced toxicities in colorectal cancer: a meta-analysis in Caucasians, Pharmacogenomics J, 14, 120, 10.1038/tpj.2013.10 · DOI
  147. Hurwitz, 2012, Registries and randomized trials in assessing the effects of bevacizumab in colorectal cancer: is there a common theme?, J Clin Oncol, 30, 580, 10.1200/JCO.2011.40.7031 · DOI
  148. Roth, 2010, Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial, J Clin Oncol, 28, 466, 10.1200/JCO.2009.23.3452 · DOI · Paper page
  149. Cremolini, 2020, Individual patient data meta-analysis of FOLFOXIRI plus bevacizumab versus doublets plus bevacizumab as initial therapy of unresectable metastatic colorectal cancer, J Clin Oncol, 38, 3314, 10.1200/JCO.20.01225 · DOI · Paper page
  150. Arnold, 2017, Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials, Ann Oncol, 28, 1713, 10.1093/annonc/mdx175 · DOI · Paper page
  151. 2019, Drug Administration Package Insert OGIVRI trastuzumab dkst for injection for intravenous use Accessed November Available at https www accessdata fda gov drugsatfda docs label lbl pdf, Food, 17
  152. Riesco-Martínez, 2016, Cost-effectiveness analysis of different sequences of the use of epidermal growth factor receptor inhibitors for wild-type KRAS unresectable metastatic colorectal cancer, J Oncol Pract, 12, e710, 10.1200/JOP.2015.008730 · DOI
  153. Helbling, 2007, Successful challenge with the fully human EGFR antibody panitumumab following an infusion reaction with the chimeric EGFR antibody cetuximab, Ann Oncol, 18, 963, 10.1093/annonc/mdm130 · doi:10.1093/annonc/mdm130
  154. Cheng, 2011, Trends in colorectal cancer incidence by anatomic site and disease stage in the United States from 1976 to 2005, Am J Clin Oncol, 34, 573, 10.1097/COC.0b013e3181fe41ed · DOI · Paper page
  155. 2019, Drug Administration Package Insert ROZLYTREK entrectinib capsules for oral use Accessed November Available at https www accessdata fda gov drugsatfda docs label lbl pdf, Food, 17, 000
  156. Wu, 2015, Does overexpression of HER-2 correlate with clinicopathological characteristics and prognosis in colorectal cancer? Evidence from a meta-analysis, Diagn Pathol, 10, 144, 10.1186/s13000-015-0380-3 · DOI
  157. Drilon, 2018, Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children, N Engl J Med, 378, 731, 10.1056/NEJMoa1714448 · DOI · Paper page
  158. Kabbinavar, 2003, Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer, J Clin Oncol, 21, 60, 10.1200/JCO.2003.10.066 · DOI · Paper page
  159. Gruenberger, 2015, Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial, Ann Oncol, 26, 702, 10.1093/annonc/mdu580 · DOI · Paper page
  160. Hochster, 2007, Use of calcium and magnesium salts to reduce oxaliplatin-related neurotoxicity, J Clin Oncol, 25, 4028, 10.1200/JCO.2007.13.5251 · doi:10.1200/jco.2007.13.5251
  161. Van Cutsem, 2001, Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study, J Clin Oncol, 19, 4097, 10.1200/JCO.2001.19.21.4097 · DOI · Paper page
  162. Alberts, 2005, Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study, J Clin Oncol, 23, 9243, 10.1200/JCO.2005.07.740 · DOI · Paper page
  163. Tejpar, 2012, Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab, J Clin Oncol, 30, 3570, 10.1200/JCO.2012.42.2592 · DOI · Paper page
  164. Loupakis, 2014, Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer, N Engl J Med, 371, 1609, 10.1056/NEJMoa1403108 · DOI · Paper page
  165. Peeters, 2015, Analysis of KRAS/NRAS mutations in a phase 3 study of panitumumab with FOLFIRI compared with FOLFIRI alone as second-line treatment of metastatic colorectal cancer, Clin Cancer Res, 21, 5469, 10.1158/1078-0432.CCR-15-0526 · DOI · Paper page
  166. Van Cutsem, 2012, Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen, J Clin Oncol, 30, 3499, 10.1200/JCO.2012.42.8201 · DOI · Paper page
  167. Buchler, 2014, Bevacizumab with 5-fluorouracil, leucovorin, and oxaliplatin versus bevacizumab with capecitabine and oxaliplatin for metastatic colorectal carcinoma: results of a large registry-based cohort analysis, BMC Cancer, 14, 323, 10.1186/1471-2407-14-323 · doi:10.1186/1471-2407-14-323
  168. Cui, 2015, Neoadjuvant chemotherapy (NCT) plus targeted agents versus NCT alone in colorectal liver metastases patients: A systematic review and meta-analysis, Oncotarget, 6, 44005, 10.18632/oncotarget.5875 · DOI
  169. Sul, 2016, FDA approval summary: pembrolizumab for the treatment of patients with metastatic non-small cell lung cancer whose tumors express programmed death-ligand 1, Oncologist, 21, 643, 10.1634/theoncologist.2015-0498 · DOI · Paper page
  170. Chen, 2014, BRAFV600E mutation and its association with clinicopathological features of colorectal cancer: a systematic review and meta-analysis, PLoS One, 9, e90607, 10.1371/journal.pone.0090607 · DOI · Paper page
  171. Shankaran, 2018, Cost-effectiveness of cetuximab as first-line treatment for metastatic colorectal cancer in the United States, Am J Clin Oncol, 41, 65, 10.1097/COC.0000000000000231 · DOI
  172. Hong, 2020, Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials, Lancet Oncol, 21, 531, 10.1016/S1470-2045(19)30856-3 · DOI · Paper page
  173. Mitry, 2008, Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials, J Clin Oncol, 26, 4906, 10.1200/JCO.2008.17.3781 · DOI · Paper page
  174. Sartore-Bianchi, 2019, HER2 positivity predicts unresponsiveness to EGFR-targeted treatment in metastatic colorectal cancer, Oncologist, 24, 1395, 10.1634/theoncologist.2018-0785 · DOI · Paper page
  175. Wen, 2013, Ca/Mg infusions for the prevention of oxaliplatin-related neurotoxicity in patients with colorectal cancer: a meta-analysis, Ann Oncol, 24, 171, 10.1093/annonc/mds211 · DOI
  176. Porschen, 2007, Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group, J Clin Oncol, 25, 4217, 10.1200/JCO.2006.09.2684 · DOI · Paper page
  177. Peeters, 2014, Final results from a randomized phase 3 study of FOLFIRI +/- panitumumab for second-line treatment of metastatic colorectal cancer, Ann Oncol, 25, 107, 10.1093/annonc/mdt523 · DOI · Paper page
  178. Sobrero, 2009, Phase IV study of bevacizumab in combination with infusional fluorouracil, leucovorin and irinotecan (FOLFIRI) in first-line metastatic colorectal cancer, Oncology, 77, 113, 10.1159/000229787 · DOI
  179. Hofheinz, Treatment with antiangiogenic drugs in multiple lines in patients with metastatic colorectal cancer: meta-analysis of randomized trials [published online August 30, 2016], Gastroenterol Res Pract
  180. Segelov, 2016, Response to cetuximab with or without irinotecan in patients with refractory metastatic colorectal cancer harboring the KRAS G13D mutation: Australasian Gastro-Intestinal Trials Group ICECREAM study, J Clin Oncol, 34, 2258, 10.1200/JCO.2015.65.6843 · DOI
  181. Price, 2015, Correlation of extended RAS and PIK3CA gene mutation status with outcomes from the phase III AGITG MAX STUDY involving capecitabine alone or in combination with bevacizumab plus or minus mitomycin C in advanced colorectal cancer, Br J Cancer, 112, 963, 10.1038/bjc.2015.37 · DOI · Paper page
  182. Meric-Bernstam, 2019, Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study, Lancet Oncol, 20, 518, 10.1016/S1470-2045(18)30904-5 · DOI · Paper page
  183. Wang, 2015, Right-sided colon cancer and left-sided colorectal cancers respond differently to cetuximab, Chin J Cancer, 34, 384, 10.1186/s40880-015-0022-x · DOI
  184. Yoshino, 2012, TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial, Lancet Oncol, 13, 993, 10.1016/S1470-2045(12)70345-5 · DOI · Paper page
  185. Fujii, 2019, Bevacizumab in combination with TAS-102 improves clinical outcomes in patients with refractory metastatic colorectal cancer: a retrospective study [published online November 20, 2019], Oncologist
  186. Aparicio, 2016, Randomized phase III trial in elderly patients comparing LV5FU2 with or without irinotecan for first-line treatment of metastatic colorectal cancer (FFCD 2001-02), Ann Oncol, 27, 121, 10.1093/annonc/mdv491 · DOI
  187. Douillard, 2013, Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer, N Engl J Med, 369, 1023, 10.1056/NEJMoa1305275 · DOI · Paper page
  188. Hartmann, 2012, Is there a difference in demography and clinical characteristics in patients treated with and without bevacizumab?, J Clin Oncol, 30, 3317, 10.1200/JCO.2012.43.3409 · doi:10.1200/jco.2012.43.3409
  189. Lewis, 2016, Programmed death-1 inhibition in cancer with a focus on non-small cell lung cancer: rationale, nursing implications, and patient management strategies, Clin J Oncol Nurs, 20, 319, 10.1188/16.CJON.319-326 · DOI
  190. Price, 2016, Final results and outcomes by prior bevacizumab exposure, skin toxicity, and hypomagnesaemia from ASPECCT: randomized phase 3 non-inferiority study of panitumumab versus cetuximab in chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer, Eur J Cancer, 68, 51, 10.1016/j.ejca.2016.08.010 · DOI
  191. 2019, Drug Administration Package Insert MVASI bevacizumab awwb injection for intravenous use Accessed November Available at https www accessdata fda gov drugsatfda docs label lbl pdf, Food, 17
  192. Besora, 2018, Rechallenge with oxaliplatin and peripheral neuropathy in colorectal cancer patients, J Cancer Res Clin Oncol, 144, 1793, 10.1007/s00432-018-2691-8 · doi:10.1007/s00432-018-2691-8
  193. Segelov, 2014, The role of biological therapy in metastatic colorectal cancer after first-line treatment: a meta-analysis of randomised trials, Br J Cancer, 111, 1122, 10.1038/bjc.2014.404 · DOI
  194. XELODA, 2019, Drug Administration Package Insert capecitabine tablets for oral use Accessed November Available at https www accessdata fda gov drugsatfda docs label lbl pdf, Food, 17, 020896
  195. XELODA, 2019, Drug Administration Package Insert capecitabine tablets for oral use Accessed November Available at https www accessdata fda gov drugsatfda docs label lbl pdf, Food, 17, 020896
  196. O’Dwyer, 2006, Uridine diphosphate glucuronosyltransferase (UGT) 1A1 and irinotecan: practical pharmacogenomics arrives in cancer therapy, J Clin Oncol, 24, 4534, 10.1200/JCO.2006.07.3031 · DOI · Paper page
  197. 2019, Drug Administration Package Insert OGIVRI trastuzumab dkst for injection for intravenous use Accessed November Available at https www accessdata fda gov drugsatfda docs label lbl pdf, Food, 17
  198. Sobrero, 2008, EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer, J Clin Oncol, 26, 2311, 10.1200/JCO.2007.13.1193 · DOI · Paper page
  199. Mauri, 2019, Retreatment with anti-EGFR monoclonal antibodies in metastatic colorectal cancer: systematic review of different strategies, Cancer Treat Rev, 73, 41, 10.1016/j.ctrv.2018.12.006 · DOI
  200. Hartmann, 2012, Is there a difference in demography and clinical characteristics in patients treated with and without bevacizumab?, J Clin Oncol, 30, 3317, 10.1200/JCO.2012.43.3409 · doi:10.1200/jco.2012.43.3409

200 of 374 shown

Cited by

See all 1,696

Metadata

Authors
Benson, A. B., Venook, A. P., Al-Hawary, M. M., Arain, M. A., Chen, Y.-J., Ciombor, K. K., Cohen, S., Cooper, H. S., Deming, D., Farkas, L., Garrido-Laguna, I., Grem, J. L., Gunn, A., Hecht, J. R., Hoffe, S., Hubbard, J., Hunt, S., Johung, K. L., Kirilcuk, N., Krishnamurthi, S., Messersmith, W. A., Meyerhardt, J., Miller, E. D., Mulcahy, M. F., Nurkin, S., Overman, M. J., Parikh, A., Patel, H., Pedersen, K., Saltz, L., Schneider, C., Shibata, D., Skibber, J. M., Sofocleous, C. T., Stoffel, E. M., Stotsky-Himelfarb, E., Willett, C. G., Gregory, K. M., & Gurski, L. A.
Venue
Journal of the National Comprehensive Cancer Network
Published
2021-03
Volume
19
Issue
3
Pages
329-359
ISSN
  • 1540-1405 (ISSN-L)
  • 1540-1413
OpenAlex
W3134887329
Cited by
1,696
References
292
FWCI
103.22
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.